前沿生物(688221):公司信息更新报告:两款siRNA管线独家授权GSK,携手推进全球合作
KAIYUAN SECURITIES· 2026-02-24 06:43
医药生物/化学制药 前沿生物(688221.SH) 两款 siRNA 管线独家授权 GSK,携手推进全球合作 2026 年 02 月 24 日 投资评级:买入(维持) | 日期 | 2026/2/13 | | --- | --- | | 当前股价(元) | 22.60 | | 一年最高最低(元) | 29.98/7.16 | | 总市值(亿元) | 84.65 | | 流通市值(亿元) | 84.65 | | 总股本(亿股) | 3.75 | | 流通股本(亿股) | 3.75 | | 近 3 个月换手率(%) | 252.45 | 股价走势图 数据来源:聚源 -50% 0% 50% 100% 150% 200% 2025-02 2025-06 2025-10 前沿生物 沪深300 相关研究报告 siRNA 管线方面,公司已有用于治疗 IgA 肾病的 FB7013(补体系统单靶点, 2025/12/31 国内 IND 申请获 CDE 受理)、FB7011(补体系统双靶点,IND enabling 阶段);FB7023(治疗 ASCVD),已确定临床前候选分子(PCC),并启动了在 自发性高血脂猕猴模型上的药效 ...
中船特气(688146):跟踪点评:AI等需求拉动电子特气放量,25年公司业绩稳健增长
EBSCN· 2026-02-24 06:24
2026 年 2 月 24 日 公司研究 AI 等需求拉动电子特气放量,25 年公司业绩稳健增长 ——中船特气(688146.SH)跟踪点评 增持(维持) 当前价:43.84 元 作者 分析师:赵乃迪 执业证书编号:S0930517050005 010-57378026 zhaond@ebscn.com 分析师:周家诺 执业证书编号:S0930523070007 021-52523675 zhoujianuo@ebscn.com 市场数据 | 总股本(亿股) | 5.29 | | --- | --- | | 总市值(亿元): | 232.09 | | 一年最低/最高(元): | 24.14/52.40 | | 近 3 月换手率: | 242.93% | 股价相对走势 -16% 4% 24% 44% 65% 02/25 05/25 08/25 11/25 中船特气 沪深300 收益表现 | % | 1M | 3M | 1Y | | --- | --- | --- | --- | | 相对 | -6.50 | 2.68 | 28.90 | | 绝对 | -7.49 | 7.45 | 46.30 | | 资料来源: ...
英科医疗: 百尺竿头,更进一步——全球丁腈手套龙头周期复苏与进阶之路
GOLDEN SUN SECURITIES· 2026-02-24 06:05
Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5][9]. Core Insights - The company is a leading manufacturer of disposable gloves, particularly nitrile gloves, and has significantly increased its production capacity from 19 billion units in 2019 to 56 billion units by mid-2025, establishing itself as a global leader in the nitrile glove market [1][15]. - The nitrile glove industry is experiencing robust demand due to its superior performance and low allergy rates, with global rubber glove demand projected to reach approximately 325 to 375 billion units by 2025, maintaining a strong growth trend [1][40]. - The company has built a strong cost advantage through technological leadership, self-supply of raw materials, and economies of scale, making it difficult for competitors to replicate its cost structure [2][47]. Company Overview - The company generates over 90% of its revenue from medical protective products, primarily nitrile and PVC gloves, with a significant portion of its sales coming from overseas markets, particularly North America and Europe [20][31]. - The management team has a stable structure, with key executives having extensive experience in the industry, contributing to the company's operational efficiency and strategic direction [27][30]. Industry Analysis - The nitrile glove market is characterized by a high-quality price ratio, with increasing penetration in various applications beyond medical use, driven by heightened public awareness of hygiene due to recent global health events [31][36]. - The supply structure of the nitrile glove market is concentrated in China and Malaysia, which together account for approximately 60% of global supply, while demand is primarily driven by the U.S. and European markets [44][45]. Financial Projections - The company is expected to achieve revenues of 10.01 billion, 12.56 billion, and 14.48 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 5.15%, 25.41%, and 15.34% [11][9]. - The projected net profit for the same years is estimated at 1.26 billion, 1.71 billion, and 2.19 billion yuan, reflecting significant growth potential in profitability [11][9].
神工股份(688233):硅材料到硅零部件一体化生产,充分受益存储扩产
China Post Securities· 2026-02-24 06:04
证券研究报告:电子 | 公司点评报告 发布时间:2026-02-24 股票投资评级 资料来源:聚源,中邮证券研究所 公司基本情况 | 最新收盘价(元) | 84.15 | | --- | --- | | 总股本/流通股本(亿股)1.70 | / 1.70 | | 总市值/流通市值(亿元)143 | / 143 | | 周内最高/最低价 52 | 106.78 / 19.30 | | 资产负债率(%) | 7.2% | | 市盈率 | 350.63 | | 第一大股东 | 更多亮照明有限公司 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 硅材料到硅零部件一体化生产,充分受益存储扩产 l 投资要点 25Q4 收入大幅增长,具备较强业绩弹性。根据公司 2025 年业绩 预告,营收方面,预告范围为4.3-4.5亿元,同比增长42.04%-48.65%, 公司前三季度单季度平均收入约为 1 亿元(未经审计),第四季度收 入 ...
东鹏饮料(605499):动态更新报告:迈向平台型公司,再迎布局时点
Yin He Zheng Quan· 2026-02-24 05:34
Investment Rating - The report maintains a "Buy" rating for the company [3][57]. Core Insights - The company is transitioning from a single-product model to a platform-based beverage giant, with energy drink sustainability and new product expansion being key factors influencing performance and stock price [8]. - The energy drink segment is expected to stabilize in the short term, with long-term growth potential remaining significant due to market expansion and increasing consumer demographics [11][14]. - New product launches, particularly in milk tea and unsweetened tea, are anticipated to catalyze sales growth in the upcoming months [18][23]. - Multiple internal and external factors are expected to contribute to margin improvement, including raw material cost reductions and operational efficiencies [29]. - The company is focusing on expanding its presence in Southeast Asia, with significant revenue potential projected for the region by 2030 [37]. Financial Forecasts - Revenue projections for 2025 to 2027 are estimated at 211 billion, 271 billion, and 330 billion CNY, respectively, with year-on-year growth rates of 33%, 28%, and 22% [48]. - The net profit for the same period is forecasted to be 45 billion, 59 billion, and 73 billion CNY, reflecting growth rates of 37%, 30%, and 23% [49]. - The company's price-to-earnings (PE) ratios are projected to be 33, 25, and 20 for the years 2025, 2026, and 2027, respectively, indicating a favorable valuation compared to industry peers [57].
雷迪克(300652):汽车轴承基本盘稳健,迈向机器人核心部件供应商
Shenwan Hongyuan Securities· 2026-02-24 05:13
上 市 公 司 公 司 研 究 / 公 司 深 度 市场数据: 2026 年 02 月 13 日 收盘价(元) 51.18 一年内最高/最低(元) 91.27/30.63 | 市净率 | 4.5 | | --- | --- | | 股息率%(分红/股价) | 0.29 | | 流通 A 股市值(百万元) | 6,127 | | 上证指数/深证成指 4,082.07/14,100.19 | | | 注:"股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产(元) | 11.34 | | 资产负债率% | 26.39 | | 总股本/流通 A 股(百万) | 133/120 | | 流通 B 股/H 股(百万) | -/- | 一年内股价与大盘对比走势: -100% 0% 100% 200% 02-13 03-13 04-13 05-13 06-13 07-13 08-13 09-13 10-13 11-13 12-13 01-13 02-13 雷迪克 沪深300指数 (收益率) 证券分析师 王珂 A023052112000 ...
英科医疗(300677):全球丁腈手套龙头周期复苏与进阶之路:百尺竿头,更进一步
GOLDEN SUN SECURITIES· 2026-02-24 02:37
Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5][9]. Core Insights - The company is a leading manufacturer of disposable gloves, particularly nitrile gloves, and has significantly expanded its production capacity from 19 billion units in 2019 to 56 billion units by mid-2025, establishing itself as a global leader in the nitrile glove market [1][15]. - The nitrile glove industry is experiencing robust demand due to its superior performance and low allergy rates, with global rubber glove demand projected to reach approximately 325 to 375 billion units by 2025, maintaining a strong growth trend [1][40]. - The company has built a strong cost advantage through technological leadership, self-supply of raw materials, and economies of scale, making it difficult for competitors to replicate its cost structure [2][47]. Company Overview - The company generates over 90% of its revenue from medical protective products, primarily nitrile and PVC gloves, with a significant portion of its sales coming from overseas markets, particularly North America and Europe [20][31]. - The management team is stable, with key executives having extensive experience in manufacturing, supply chain management, and international sales [27][30]. Industry Analysis - The nitrile glove market is characterized by a high-quality price ratio, with increasing penetration in various applications beyond medical use, driven by heightened public health awareness [31][36]. - The supply structure is dominated by manufacturers from Malaysia and China, with the demand primarily concentrated in the U.S. and Europe, which account for about 60% of global consumption [44][45]. Financial Projections - The company is expected to achieve revenues of 10.01 billion, 12.56 billion, and 14.48 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 5.15%, 25.41%, and 15.34% [11][9]. - The net profit forecast for the same period is projected to be 1.26 billion, 1.71 billion, and 2.19 billion yuan, reflecting growth rates of -14.1%, 36.2%, and 27.9% [11][9].
万辰集团:门店模型持续优化,Q1业绩增长有望超预期-20260224
China Post Securities· 2026-02-24 01:25
证券研究报告:食品饮料 | 公司深度报告 发布时间:2026-02-23 股票投资评级 资料来源:聚源,中邮证券研究所 公司基本情况 ⚫ 投资要点 节前我们集中性进行了量贩零售业态实地调研,本次调研覆盖石 家庄、成都、郑州、长沙、汕头等地核心商圈的好想来、零食很忙、 零食有鸣等竞品门店进行对比观察。调研时间集中于 2026 年 1-2 月, 正值春节消费旺季,能够充分反映各品牌的实际运营状态和消费者行 为特征。我们认为未来行业将呈现以鸣鸣很忙、好想来引领的全国性 量贩巨头+区域性品牌+传统零售跨界融合长期并存的割据格局。 结合调研感受及业绩考量,我们认为万辰集团作为头部零食量贩 品牌具备龙头效应及业绩弹性,在此重申推荐逻辑。经过 2024 年至 2025 年的密集开店与市场培育,万辰集团量贩零食业务已迎来关键经 营拐点。从单店趋势看,老店业绩企稳、新店爬坡完成,叠加升级店 型对单店 GMV 的提振作用逐步显现;从外部催化看,2026 年春节时点 靠后带来的消费集中效应,有望在 1-2 月形成显著旺季脉冲。 1)驱动因素一:老店企稳、新店爬坡,开店节奏有序提升。24H2 集中开设的新店(尤其是两湖两广新市场门店 ...
宝立食品:复调创新+C端轻烹,宝立领航“食”尚-20260224
GOLDEN SUN SECURITIES· 2026-02-24 01:20
Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5]. Core Insights - Baoli Foods has established itself as a leader in the Western compound seasoning industry, evolving from single product offerings to comprehensive solutions over its 20-year history [15][16]. - The company has shown steady revenue and profit growth, with a projected CAGR of 14.09% from 2022 to 2024, and a net profit of 1.92 billion yuan in Q1-Q3 2025, reflecting a year-on-year increase of 10.59% [1][15]. - The compound seasoning market is expected to grow from 99.7 billion yuan in 2020 to 126.5 billion yuan by 2024, with a CAGR of 6.1% [2]. Company Overview - Baoli Foods operates three main business segments: compound seasonings, light cooking solutions, and beverage dessert ingredients, serving both B-end and C-end markets [15]. - The company has a stable management team with extensive industry experience, which supports strategic execution and innovation [26][29]. - The financial performance indicates a robust growth trajectory, with revenue expected to reach 2.998 billion yuan in 2025, reflecting a year-on-year growth rate of 13.1% [10]. Industry Analysis - The compound seasoning market is characterized by strong demand from both enterprise and individual customers, with enterprise customer revenue projected to grow from 58.8 billion yuan to 73.1 billion yuan from 2020 to 2024, and individual customer revenue expected to increase from 40.9 billion yuan to 53.4 billion yuan [2]. - The restaurant service market in China is projected to reach 5.6 trillion yuan by 2024, with a CAGR of 8.78% from 2020 to 2024, driven by the growth of chain restaurants and the takeout market [3]. - The C-end market for pre-prepared meals is expected to grow significantly, with the market size projected to increase from 171.2 billion yuan in 2019 to 485 billion yuan by 2024, achieving a CAGR of 23.15% [4].
松原股份:本土汽车被动安全新星,业绩高增迈向全球-20260224
KAIYUAN SECURITIES· 2026-02-24 00:30
汽车/汽车零部件 松原安全(300893.SZ) 本土汽车被动安全新星,业绩高增迈向全球 2026 年 02 月 23 日 投资评级:买入(首次) | 日期 | 2026/2/13 | | --- | --- | | 当前股价(元) | 23.44 | | 一年最高最低(元) | 41.16/22.45 | | 总市值(亿元) | 110.87 | | 流通市值(亿元) | 58.80 | | 总股本(亿股) | 4.73 | | 流通股本(亿股) | 2.51 | | 近 3 个月换手率(%) | 94.41 | 股价走势图 数据来源:聚源 -20% 0% 20% 40% 60% 80% 2025-02 2025-06 2025-10 松原安全 沪深300 | 邓健全(分析师) | 赵悦媛(分析师) | 赵旭杨(分析师) | | --- | --- | --- | | dengjianquan@kysec.cn | zhaoyueyuan@kysec.cn | zhaoxuyang@kysec.cn | | 证书编号:S0790525090003 | 证书编号:S0790525100003 | 证书编号:S ...